Regenxbio (RGNX) Names Olivier Danos, Ph.D as Chief Scientific Officer – StreetInsider.com

Posted: March 28, 2017 at 8:43 am

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced that Olivier Danos, Ph.D., is joining REGENXBIO in the newly created position of Chief Scientific Officer. Dr. Danos will report to Kenneth T. Mills, REGENXBIOs President and Chief Executive Officer.

Dr. Danos joins REGENXBIO from Biogen Inc., where he was Senior Vice President, Cell and Gene Therapy. At Biogen, Dr. Danos led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering. Dr. Danos also co-founded and is an executive member of the board of directors of Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates for the treatment of Mucopolysaccharidosis Type IIIA.

Olivier brings established industry leadership and scientific expertise in the development of gene therapies and the field of genome engineering to REGENXBIO, said Dr. James M. Wilson, M.D., Ph.D. REGENXBIOs scientific founder and director of the University of Pennsylvania (Penn) Gene Therapy Program. My relationship with Olivier can be traced back to the early stages of our careers, when he and I shared a bench at the Whitehead laboratories. He is an innovative scientist who has been at the forefront of the industry, and I look forward to collaborating with him on the advancement of scientific research at REGENXBIO.

We are excited to enhance the breadth and depth of our scientific research team. Olivier and Jim are two renowned gene therapy pioneers who have been key players in the success of the field, said Mr. Mills. We look forward to leveraging Oliviers rich industry experience and remarkable understanding of the space, including his work with the NAV Technology Platform, as we build a robust clinical pipeline of gene therapy product candidates with the goal of improving treatment options in many diseases.

The NAV Technology Platform has the potential to significantly alter the course of disease and deliver enhanced health outcomes to patients in need, said Dr. Danos. I am thrilled to have the opportunity to lead scientific research at REGENXBIO as we continue to advance this groundbreaking technology in a broad range of diseases that are not effectively addressed by existing drug classes.

Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Earlier in his career, Dr. Danos was Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation. Dr. Danos has directed research focused on gene therapy at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris.

Dr. Danos received a Ph.D. in Biology at the University of Paris Diderot and the Pasteur Institute, and a Master in Science in Genetics and Mathematics from the University of Paris Orsay. Dr. Danos is a founding member of the European Society of Gene and Cell Therapy.

Original post:
Regenxbio (RGNX) Names Olivier Danos, Ph.D as Chief Scientific Officer - StreetInsider.com

Related Posts

Comments are closed.

Archives